Why IMU is a multi multi bagger, page-29303

I believe the results from the first trial were 40% longer than chemo alone, which I believe is a little better than Trastuzumab, but not by much. I think the bigger story to tell is that the HER-Vaxx safety profile makes it a good candidate for combination therapies, such as combined with Vaxinia or onCARlytics if they eventual come to market, &/or with an anti-PD1. Hitting the cancer with multiple therapies is probably a better approach than trying to rely on the hope a single agent will be 100% effective.

We're still waiting on results from the other HER-Vaxx Ph2 Clinical Trial:

A Study of IMU-131 (HER-Vaxx) in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/neu Over-Expressing Gastric Cancer (nextHERIZON)

https://clinicaltrials.gov/study/NCT05311176

I believe they have 12 months after the completion date (04-04-2024) to release the results unless they obtain an extension.